The Oil & Gas Journal, first published in 1902, is the world's most widely read petroleum industry publication. OGJ delivers international oil and gas industry news; analysis of issues and events; practical technology for design, operation, and maintenance of oil and gas operations; and important statistics on energy markets and industry activity.

OGJ is edited to meet the needs of engineers, geoscientists, managers, and executives throughout the oil and gas industry. It is part of Endeavor Business Media, Nashville, Tenn., which also publishes Offshore Magazine.

Endeavor Business Media’s Petroleum Group also produces targeted e-Newsletters; hosts global conferences and exhibitions, seminars, and forums; and publishes directories, technical books, print and electronic databases, surveys, and maps.

Additional Information

Website & Technical Help

For help with subscription purchases or refunds, or trouble logging into the paid subscription content on www.ogj.com, please contact Customer Service at [email protected] or call 1-847-559-7598.

For more customer service information, please click here.

Oxford Cannabinoid Technologies announces "potential breakthrough" in field of oncology

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) Clarissa Sowemimo-Coker speaks to Thomas Warner from Proactive London after announcing what the prescription cannabinoid medicine company calls a "potential breakthrough" for the treatment of solid tumours.

Sowemimo-Coker gives an overview of the announcements, highlighting promising early-stage data, promising, and says Oxford Cannabinoid Technologies is aiming to provide a convenient oral dose form for patients, significantly reducing costs and improving accessibility. The expansion into oncology aligns with OCT's strategy to explore various realms of medicine beyond their initial focus on pain.

Sowemimo-Coker says that the company's collaboration agreement with Canopy Growth has already borne fruit, with more potential derivatives waiting to be explored. She also touches on the recent appointment of Dr. Tim Corn as Chief Medical Officer, with a view to advancing clinical trials and overall progress, and concludes by saying that an investor meeting is being held later this week.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.